[
  {
    "nct_id": "NCT05565248",
    "brief_title": "An Open-Label, FIH Study Evaluating the Safety, Tolerability, and Efficacy of VCTX211 Combination Product in Subjects With T1D",
    "official_title": "An Open-Label, First-in-Human Study Evaluating the Safety, Tolerability, and Efficacy of VCTX211 Combination Product in Subjects With Type 1 Diabetes Mellitus (T1D)",
    "overall_status": "RECRUITING",
    "start_date": "2023-01-20",
    "completion_date": "2025-08",
    "brief_summary": "This is an open-label, multicenter, Phase 1/2 study evaluating the Safety, Tolerability, and Efficacy of VCTX211 Combination Product in Subjects with T1D",
    "detailed_description": "VCTX211 combination product (unit) compromises 2 components: (1) allogeneic pancreatic endoderm cells (PEC211) genetically modified using Cluster Regularly Interspaced Short Palindromic Repeats/ CRISPR-associated protein 9 (CRISPR/Cas9) to promote immune evasiveness and survival, and (2) a durable, removable, perforated device designed to deliver and retain PEC211 cells.",
    "sponsor": "CRISPR Therapeutics AG",
    "collaborators": [
      "ViaCyte"
    ],
    "conditions": [
      "Diabetes Mellitus",
      "Diabetes Mellitus, Type 1",
      "Glucose Metabolism Disorders",
      "Metabolic Disease",
      "Endocrine System Diseases",
      "Autoimmune Diseases",
      "Immune System Diseases"
    ],
    "interventions": [],
    "phases": [
      "PHASE1",
      "PHASE2"
    ],
    "study_type": "INTERVENTIONAL"
  },
  {
    "nct_id": "NCT06492304",
    "brief_title": "A Safety and Efficacy Study Evaluating CTX131 in Adult Subjects With Relapsed/Refractory Hematologic Malignancies",
    "official_title": "A Phase 1/2 Dose Evaluation and Cohort Expansion Study of the Safety and Efficacy of Anti-CD70 Allogeneic CRISPR-Cas9-Engineered T Cells (CTX131) in Adult Subjects With Relapsed/Refractory Hematologic Malignancies",
    "overall_status": "RECRUITING",
    "start_date": "2024-08-13",
    "completion_date": "2030-11",
    "brief_summary": "This is an open label, multicenter, phase 1/2 dose evaluation and cohort expansion study evaluating the safety and efficacy of CTX131 in subjects with Relapsed/Refractory Hematologic Malignancies",
    "detailed_description": "The study may enroll up to 290 subjects in total. CTX131 is a CD70-directed chimeric antigen receptor (CAR) T cell immunotherapy comprised of allogeneic T cells prepared for the treatment of relapsed/refractory hematological malignancies. The cells are from healthy adult volunteer donors that are genetically modified ex vivo using CRISPR-Cas9 (clustered regularly interspaced short palindromic repeats/ CRISPR-associated protein 9) gene editing components (single guide RNA and Cas9 nuclease)",
    "sponsor": "CRISPR Therapeutics",
    "collaborators": [],
    "conditions": [
      "T Cell Lymphoma",
      "B Cell Lymphoma",
      "Acute Myeloid Leukemia"
    ],
    "interventions": [],
    "phases": [
      "PHASE1",
      "PHASE2"
    ],
    "study_type": "INTERVENTIONAL"
  },
  {
    "nct_id": "NCT05795595",
    "brief_title": "A Safety and Efficacy Study Evaluating CTX131 in Adult Subjects With Relapsed or Refractory Solid Tumors",
    "official_title": "A Phase 1/2, Open-label, Multicenter, Dose Escalation and Cohort Expansion Study of the Safety and Efficacy of Anti-CD70 Allogeneic CRISPR-Cas9-Engineered T Cells (CTX131) in Adult Subjects With Relapsed or Refractory Solid Tumors",
    "overall_status": "RECRUITING",
    "start_date": "2023-03-13",
    "completion_date": "2030-05",
    "brief_summary": "This is an open-label, multicenter, Phase 1/2 study evaluating the safety and efficacy of CTX131\u2122 in subjects with relapsed or refractory solid tumors.",
    "detailed_description": "An open-label, multi-center Phase 1/2 study of CTX131 in subjects with relapsed/refractory solid tumors. CTX131 is an is allogeneic CD70- directed chimeric antigen receptor (CAR) T cell immunotherapy comprised of allogeneic T cells that are genetically modified ex vivo using CRISPR-Cas9 (clustered regularly interspaced short palindromic repeats/ CRISPR associated protein 9) gene editing components (single guide RNA and Cas9 nuclease).",
    "sponsor": "CRISPR Therapeutics AG",
    "collaborators": [],
    "conditions": [
      "Clear Cell Renal Cell Carcinoma",
      "Cervical Carcinoma",
      "Esophageal Carcinoma",
      "Pancreatic Adenocarcinoma",
      "Malignant Pleural Mesothelioma"
    ],
    "interventions": [],
    "phases": [
      "PHASE1",
      "PHASE2"
    ],
    "study_type": "INTERVENTIONAL"
  },
  {
    "nct_id": "NCT05329649",
    "brief_title": "Evaluation of Safety and Efficacy of CTX001 in Pediatric Participants With Severe Sickle Cell Disease (SCD)",
    "official_title": "A Phase 3 Study to Evaluate the Safety and Efficacy of a Single Dose of CTX001 in Pediatric Subjects With Severe Sickle Cell Disease",
    "overall_status": "RECRUITING",
    "start_date": "2022-05-02",
    "completion_date": "2026-05",
    "brief_summary": "This is a single-dose, open-label study in pediatric participants with severe SCD and hydroxyurea (HU) failure or intolerance. The study will evaluate the safety and efficacy of autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells (hHSPCs) (CTX001).",
    "detailed_description": "No detailed description",
    "sponsor": "Vertex Pharmaceuticals Incorporated",
    "collaborators": [
      "CRISPR Therapeutics"
    ],
    "conditions": [
      "Sickle Cell Disease",
      "Hydroxyurea Failure",
      "Hydroxyurea Intolerance",
      "Hemoglobinopathies",
      "Hematological Diseases"
    ],
    "interventions": [],
    "phases": [
      "PHASE3"
    ],
    "study_type": "INTERVENTIONAL"
  },
  {
    "nct_id": "NCT05356195",
    "brief_title": "Evaluation of Safety and Efficacy of CTX001 in Pediatric Participants With Transfusion-Dependent \u03b2-Thalassemia (TDT)",
    "official_title": "A Phase 3 Study to Evaluate the Safety and Efficacy of a Single Dose of CTX001 in Pediatric Subjects With Transfusion-Dependent \u03b2-Thalassemia",
    "overall_status": "RECRUITING",
    "start_date": "2022-05-03",
    "completion_date": "2026-05",
    "brief_summary": "This is a single-dose, open-label study in pediatric participants with TDT. The study will evaluate the safety and efficacy of autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells (hHSPCs) (CTX001).",
    "detailed_description": "No detailed description",
    "sponsor": "Vertex Pharmaceuticals Incorporated",
    "collaborators": [
      "CRISPR Therapeutics"
    ],
    "conditions": [
      "Beta-Thalassemia",
      "Thalassemia",
      "Genetic Diseases, Inborn",
      "Hematologic Diseases",
      "Hemoglobinopathies"
    ],
    "interventions": [],
    "phases": [
      "PHASE3"
    ],
    "study_type": "INTERVENTIONAL"
  },
  {
    "nct_id": "NCT05643742",
    "brief_title": "A Safety and Efficacy Study Evaluating CTX112 in Subjects With Relapsed or Refractory B-Cell Malignancies",
    "official_title": "A Phase 1/2, Open-Label, Multicenter, Dose Escalation and Cohort Expansion Study of the Safety and Efficacy of Anti-CD19 Allogeneic CRISPR-Cas9-Engineered T Cells (CTX112) in Subjects With Relapsed or Refractory B Cell Malignancies",
    "overall_status": "RECRUITING",
    "start_date": "2023-03-10",
    "completion_date": "2030-02",
    "brief_summary": "This is an open-label, multicenter, Phase 1/2 study evaluating the safety and efficacy of CTX112\u2122 in subjects with relapsed or refractory B-cell malignancies.",
    "detailed_description": "This is an open-label, multi-center Phase 1/2 study of CTX112 in subjects with relapsed/refractory B cell malignancies. CTX112 is an is allogeneic CD19-directed chimeric antigen receptor (CAR) T cell immunotherapy comprised of allogeneic T cells that are genetically modified ex vivo using CRISPR-Cas9 (clustered regularly interspaced short palindromic repeats/ CRISPR associated protein 9) gene editing components (single guide RNA and Cas9 nuclease).",
    "sponsor": "CRISPR Therapeutics AG",
    "collaborators": [],
    "conditions": [
      "B-cell Lymphoma",
      "Non-Hodgkin Lymphoma",
      "B-cell Malignancy",
      "Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)",
      "Follicular Lymphoma",
      "Mantle Cell Lymphoma",
      "Marginal Zone Lymphoma",
      "Large B-cell Lymphoma"
    ],
    "interventions": [],
    "phases": [
      "PHASE1",
      "PHASE2"
    ],
    "study_type": "INTERVENTIONAL"
  },
  {
    "nct_id": "NCT06925542",
    "brief_title": "A Safety and Efficacy Study Evaluating CTX112 in Adult Subjects With Refractory Autoimmune Disease",
    "official_title": "A Phase 1 Dose Evaluation Study of the Safety and Preliminary Efficacy of Anti-CD19 Allogeneic CRISPR-Cas9-Engineered T Cells (CTX112) in Adult Subjects With Refractory Autoimmune Disease",
    "overall_status": "RECRUITING",
    "start_date": "2025-03-10",
    "completion_date": "2031-12-31",
    "brief_summary": "This is a single-arm, open-label, multicenter, ascending dose Phase 1 study evaluating the safety and preliminary efficacy of CTX112 in adult subjects with refractory autoimmune diseases, including active systemic lupus erythematosus (SLE), systemic sclerosis (SSc), or idiopathic inflammatory myopathy (IIM).",
    "detailed_description": "This study may enroll up to 80 subjects in total. CTX112 is a CD19 directed chimeric antigen receptor (CAR) T cell immunotherapy comprised of allogeneic T cells prepared for the treatment of refractory autoimmune diseases. The cells are from healthy adult volunteer donors that are genetically modified ex vivo using CRISPR-Cas9 (clustered regularly interspaced short palindromic repeats/ CRISPR-associated protein 9) gene editing components (single guide RNA and Cas9 nuclease).",
    "sponsor": "CRISPR Therapeutics",
    "collaborators": [],
    "conditions": [
      "SLE (Systemic Lupus)",
      "Lupus Erythematosus, Systemic",
      "Lupus Nephritis",
      "Systemic Sclerosis",
      "Inflammatory Myopathy, Idiopathic",
      "Myositis",
      "Diffuse Cutaneous Systemic Sclerosis"
    ],
    "interventions": [],
    "phases": [
      "PHASE1"
    ],
    "study_type": "INTERVENTIONAL"
  },
  {
    "nct_id": "NCT03745287",
    "brief_title": "A Safety and Efficacy Study Evaluating CTX001 in Subjects With Severe Sickle Cell Disease",
    "official_title": "A Phase 1/2/3 Study to Evaluate the Safety and Efficacy of a Single Dose of Autologous CRISPR-Cas9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells (CTX001) in Subjects With Severe Sickle Cell Disease",
    "overall_status": "ACTIVE_NOT_RECRUITING",
    "start_date": "2018-11-27",
    "completion_date": "2025-07",
    "brief_summary": "This is a single-arm, open-label, multi-site, single-dose Phase 1/2/3 study in subjects with severe sickle cell disease (SCD). The study will evaluate the safety and efficacy of autologous CRISPR-Cas9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells (hHSPCs) using CTX001.",
    "detailed_description": "No detailed description",
    "sponsor": "Vertex Pharmaceuticals Incorporated",
    "collaborators": [
      "CRISPR Therapeutics"
    ],
    "conditions": [
      "Sickle Cell Disease",
      "Hematological Diseases",
      "Hemoglobinopathies"
    ],
    "interventions": [],
    "phases": [
      "PHASE2",
      "PHASE3"
    ],
    "study_type": "INTERVENTIONAL"
  },
  {
    "nct_id": "NCT03655678",
    "brief_title": "A Safety and Efficacy Study Evaluating CTX001 in Participants With Transfusion-Dependent \u03b2-Thalassemia",
    "official_title": "A Phase 1/2/3 Study of the Safety and Efficacy of a Single Dose of Autologous CRISPR-Cas9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells (hHSPCs) in Subjects With Transfusion-Dependent \u03b2-Thalassemia",
    "overall_status": "ACTIVE_NOT_RECRUITING",
    "start_date": "2018-09-14",
    "completion_date": "2025-12-08",
    "brief_summary": "This is a single-arm, open-label, multi-site, single-dose Phase 1/2/3 study in participans with transfusion-dependent \u03b2-thalassemia (TDT). The study will evaluate the safety and efficacy of autologous CRISPR-Cas9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells (hHSPCs) using CTX001.",
    "detailed_description": "No detailed description",
    "sponsor": "Vertex Pharmaceuticals Incorporated",
    "collaborators": [
      "CRISPR Therapeutics"
    ],
    "conditions": [
      "Beta-Thalassemia",
      "Thalassemia",
      "Genetic Diseases, Inborn",
      "Hematologic Diseases",
      "Hemoglobinopathies"
    ],
    "interventions": [],
    "phases": [
      "PHASE2",
      "PHASE3"
    ],
    "study_type": "INTERVENTIONAL"
  }
]